4//SEC Filing
Dunlop A. Sinclair 4
Accession 0001127602-25-000419
CIK 0001492422other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 4:17 PM ET
Size
8.1 KB
Accession
0001127602-25-000419
Insider Transaction Report
Form 4
Dunlop A. Sinclair
Director
Transactions
- Award
Common Stock
2025-01-01+6,267→ 158,393 total - Award
Stock Option (Right to Buy)
2025-01-01+11,199→ 11,199 totalExercise: $31.91Exp: 2032-12-31→ Common Stock (11,199 underlying)
Holdings
- 100,000(indirect: Indirect Owner (Epidarex))
Common Stock
Footnotes (3)
- [F1]This restricted stock unit was granted on January 1, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
- [F2]The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
- [F3]This option was granted on January 1, 2025. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001721108
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 4:17 PM ET
- Size
- 8.1 KB